ARTICLE | Management Tracks
Plus: CCO Olinger leaving Amylyx and updates from Coherus, Compass and NanoMosaic
By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst
December 9, 2023 12:19 AM UTC
Bristol Myers Squibb Co. (NYSE:BMY) confirmed that EVP, Strategy and Business Development Elizabeth Mily would leave the company, and that it is searching for a successor. Mily worked on several high-profile BMS acquisitions, including those of Mirati Therapeutics Inc. (NASDAQ:MRTX), MyoKardia Inc. and Turning Point Therapeutics Inc.
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) disclosed in an SEC filing the departure of Chief Commercial Officer Margaret Olinger, effective Dec. 31. Amylyx added that it too is searching for a successor…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/650868/bms-dealmaker-mily-to-depart